Is Foundayo Covered by Insurance? Complete 2026 Guide

Foundayo (orforglipron) became the first oral nonpeptide GLP-1 receptor agonist approved by the FDA for chronic weight management on April 1, 2026. If you have been prescribed Foundayo — or are considering it — one of the biggest questions is whether your insurance will cover the cost. The answer depends on what type of insurance you have, your plan's formulary status, and whether you meet prior authorization criteria.

This guide covers every major insurance pathway, self-pay options, and practical tips for getting coverage approved.

Current State: April 2026

Foundayo received FDA approval on April 1, 2026. However, most insurance formularies have not yet added it. Pharmacy benefit managers (PBMs) typically take 30–90 days after FDA approval to evaluate a new medication, negotiate pricing, and place it on a formulary tier. As of mid-April 2026, only a handful of large employer plans and national insurers have confirmed formulary inclusion. This gap means many patients will initially face higher out-of-pocket costs or need to use manufacturer assistance programs while formulary decisions are finalized through Q2 and Q3 2026.

Commercial Insurance Coverage

For commercially insured patients, Foundayo coverage is expanding but not universal. Key points:

• Prior authorization (PA) is almost always required. Your prescriber must submit documentation proving medical necessity.
• Step therapy may be imposed by some plans, meaning you must first try and fail on lower-cost interventions (lifestyle counseling, phentermine, orlistat, or other weight loss medications) before Foundayo is approved.
• Formulary tier placement varies. Foundayo is likely to land on Tier 3 (preferred brand) or Tier 4 (specialty) for most plans, with copays ranging from $50 to $200 without additional assistance.
• Some employers are proactively adding GLP-1 coverage as part of their benefits strategy. Ask your HR department or benefits coordinator whether Foundayo is covered under your specific plan.

Lilly Savings Card: Pay as Low as $25/Month

Eli Lilly offers a manufacturer savings card for Foundayo. Eligible commercially insured patients can reduce their out-of-pocket cost to as low as $25 per month, regardless of dose. To enroll:

• Visit foundayo.lilly.com
• Complete the enrollment form with your insurance and prescription information
• Present the savings card at your pharmacy when filling your prescription

Important: The Lilly Savings Card is not available to patients on Medicare, Medicaid, Tricare, or any other government-funded insurance program. Cash-pay patients without any insurance may also qualify for separate Lilly assistance programs — check the website for current eligibility.

Self-Pay Without Insurance: LillyDirect Pricing

Patients without insurance coverage — or those who prefer to bypass insurance — can purchase Foundayo directly through LillyDirect with free home delivery. Monthly pricing as of April 2026:

Dose	Monthly Price
0.8 mg (starting dose)	$149/month
2.5 mg	$199/month
5.5 mg / 9 mg	$299/month
14.5 mg / 17.2 mg (maintenance)	$349/month

For a detailed breakdown of pricing and cost-saving strategies, see our Foundayo cost and pricing guide.

Medicare Part D: GLP-1 Bridge Program (July 1, 2026)

Starting July 1, 2026, Medicare beneficiaries will gain access to Foundayo through the new Medicare GLP-1 Bridge Program. This is historic — Medicare has never previously covered anti-obesity medications. Key details:

• Available to enrollees in a standalone Part D plan (PDP) or Medicare Advantage plan with drug coverage (MA-PD)
• Prior authorization required: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Expected patient cost: approximately $50 per month
• Manufacturers provide the drug at a net price of $245 per quarter to CMS

For the full breakdown, read our Foundayo Medicare coverage guide.

Medicaid: State-by-State Variation

Medicaid coverage for anti-obesity medications (AOMs) varies significantly by state. As of April 2026, many state Medicaid programs do not cover weight loss medications. However, the federal BALANCE Model — launching in May 2026 — is designed to expand Medicaid access to GLP-1s in participating states. Contact your state Medicaid office or managed care organization to ask about current Foundayo coverage and whether your state is participating in the BALANCE initiative.

How to Check Your Coverage

To find out if Foundayo is covered by your specific plan:

• Call the member services number on the back of your insurance card
• Ask specifically about coverage for "Foundayo, also known as orforglipron"
• Ask about prior authorization requirements, step therapy policies, and formulary tier placement
• Request a copy of your plan's formulary if one is not available online
• Ask whether the Lilly Savings Card can be applied to your copay

Prior Authorization Tips

To maximize your chances of PA approval, work with your prescriber to include:

• Documented BMI — measured within the last 6 months, showing ≥30 (or ≥27 with comorbidities)
• List of weight-related comorbidities — hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease, or osteoarthritis
• Prior weight loss attempts — documentation of dietary interventions, exercise programs, behavioral therapy, or previous medications tried and failed
• Full clinical justification — a letter of medical necessity from your provider explaining why Foundayo is the most appropriate therapy for your situation

Coverage Comparison by Insurance Type

Insurance Type	Coverage Status	Prior Auth?	Est. Monthly Cost	Notes
Commercial Insurance	Limited (expanding)	Yes	$0–$25 (with savings card)	Step therapy common; formulary placement pending
Medicare Part D (PDP/MA-PD)	Yes (July 1, 2026)	Yes	~$50	GLP-1 Bridge Program; historic first
Medicaid	Varies by state	Yes	$0–variable	BALANCE Model expanding May 2026
Self-Pay (LillyDirect)	Full access	No	$149–$349	No insurance required; free delivery

Appeal Process if Denied

If your prior authorization is denied, you have the right to appeal. The standard process:

• Step 1: Request the denial reason in writing from your insurer.
• Step 2: Submit additional clinical documentation — updated BMI, new lab results, letters from specialists, or documentation of failed prior treatments.
• Step 3: Request a peer-to-peer review — your prescriber speaks directly with the insurance company's medical director to argue for coverage.
• Step 4: If the internal appeal fails, file an external appeal through your state's insurance commissioner or state-level appeals board.

Most denials are overturned on appeal when adequate documentation is provided. Your prescriber's office should be familiar with this process and can help advocate on your behalf.

Medical Disclaimer

Foundayo (orforglipron) is a prescription medication approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It is not for use in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.